Keyword: Pharmaceutical Care Management Association
Pharma CEOs went before the Senate last month, and now it’s PBMs’ turn to be on the hot seat.
PCMA released a statement calling HHS' proposed rule on prescription drug rebates for Medicare and Medicaid beneficiaries “poorly conceived."
Thanks to a bill introduced in Congress on Wednesday, drug rebates in commercial plans are on the chopping block.
The current structure of reimbursement for drugs in the U.S. is “regressive” and ultimately hurting patients, pharmaceutical executives said Tuesday.
Democrats have officially revealed a plan to let people ages 50 and over buy in to Medicare, plus more insurance news.
PBMs are hitting back against critics who blame them for rising drug prices, as the system they use to negotiate rebates hangs in the balance.
The Trump administration wants to eliminate safe harbor protections for drug rebates negotiated by pharmacy benefit managers.
UnitedHealthcare will pull out of the Health Care Cost Institute research collaborative, plus more insurance headlines.
A report backed by New York pharmacists found that PBMs are marking up generics in the state's Medicaid program. The group is calling for an audit.
Despite railing against the role of middlemen—namely PBMs—in rising drug prices, HHS appears poised to introduce some into Part B.